4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine | 182416-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine
• 英文别名: 4-(2-pyrimidinyl)-1,2,5,6-tetrahydropyridine；4-(2-pyrimidinyl)-1,2,3-6-tetrahydropyridine；2-(1,2,3,6-Tetrahydropyridin-4-YL)pyrimidine
• CAS: 182416-04-2
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: JPAUOLFYUGJWGM-UHFFFAOYSA-N

物化性质

• 沸点：
  199.1±40.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine 在 sodium borohydrid 作用下， 以 乙醇 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 以95%的产率得到1-benzyl-4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  Benzoxazepine derivatives and their salts and medicaments containing the same

  摘要：

  一种具有通式（I）的苯并噁唑啉衍生物及其盐和含有相同有效成分的药物： 其中，n为2至5的整数，R1表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基碳基团、C1至C4的卤代烷基团、氰基或酯基，R2表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基团或羟基，虚线表示结合键的存在或缺失，W表示C、CH或CH2或氮原子，但当W为氮原子时，Z与W结合，虚线表示缺少结合，Z表示未取代或取代的芳香烃环基团或未取代或取代的杂环基团）。 这种苯并噁唑啉衍生物及其盐可用作治疗焦虑神经症、恐惧症、强迫症、精神分裂症、心脏创伤后应激、抑郁症、心身疾病和其他精神神经病性障碍、进食障碍、更年期障碍、婴儿孤独症以及伴有脑梗死和脑出血的脑循环系统紊乱或呕吐症的药物。

  公开号：

  US06187769B1
• 作为产物：
  描述：

  4-amidinopyridine hydrochloride 在 sodium tetrahydroborate 、 1-氯乙基氯甲酸酯 作用下， 以 1,4-二氧六环 、 乙醇 、 1,2-二氯乙烷 、 乙腈 为溶剂， 生成 4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects

  摘要：

  A series of new piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives were synthesized. Among these compounds, 4-methyl-2-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidine derivative 23 (SUN N5147) exhibited sub-nanomolar affinity for 5-HT1A receptor with 1000-fold selectivity over both dopamine D-2 and alpha(1)-adrenergic receptors and remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.059

文献信息

• Pyrimidine derivatives and their salts, useful for making benzoxazepine derivatives
  申请人：Suntory Limited

  公开号：US06337397B1

  公开（公告）日：2002-01-08

  A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R1 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxyalkyl group, C1 to C4 halogenoalkyl group, cyano group, or ester group, R2 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxy group, or hydroxy group, a dotted line indicates the presence or absence of a binding bond, W indicates C, CH, or CH2 or a nitrogen atom, provided that, when W is a nitrogen atom, Z is bonded to W and the dotted line indicates the absence of a bond, and Z indicates an unsubstituted or substituted aromatic hydrocarbon ring group or an unsubstituted or substituted heterocyclic group).

  一种具有通式（I）的苯并噁唑啉衍生物及其盐和含有其作为有效成分的药物： 其中，n为2至5的整数，R1表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基碳基团、C1至C4的卤代烷基团、氰基或酯基，R2表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基团或羟基，虚线表示结合键的存在或缺失，W表示C、CH或CH2或氮原子，但当W为氮原子时，Z与W结合，虚线表示缺少结合，Z表示未取代或取代的芳香烃环基团或未取代或取代的杂环基团。
• [EN] 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA<br/>[FR] 1,2,4-TRIAZOLES COMME MODULATEURS ALLOSTÉRIQUES DE L'ACTIVITÉ DES RÉCEPTEURS MGLU5 POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DE LA DÉMENCE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013083741A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

  这项发明涉及公式（I）化合物的用途，它们作为mGlu5受体活性的正变构调节剂，包含这些化合物的药物组合物，以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的方法，如精神分裂症或认知衰退，例如痴呆或认知障碍。A、B、X、R1、R2、R3的含义在描述中给出。
• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130150341A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R 1 , R 2 , R 3 have meanings given in the description.

  本发明涉及式I化合物、它们作为mGlu5受体活性的正变构调节剂的应用、含有该化合物的药物组合物，以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的剂，如精神分裂症或认知下降，如痴呆或认知障碍。A、B、X、R1、R2、R3的含义如说明书中所述。
• 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10336729B2

  公开（公告）日：2019-07-02

  The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及式（I）（其中 R1 至 R3 和 A 如说明书和权利要求书中所定义）的新苯甲腈衍生物，涉及它们的药物、它们的治疗使用方法和含有它们的药物组合物。
• Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10730850B2

  公开（公告）日：2020-08-04

  The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及式中 X 选自以下组成的组的新杂芳基衍生物：N和CH；X选自由下列各项组成的组X1和X2中至少有一个是N），A如说明书和权利要求书中所定义，本发明涉及它们作为药物的用途、治疗方法和含有它们的药物组合物。